Skip to main content
Michael Lattanzi, MD, Oncology, Austin, TX

MichaelWilliamLattanziMD

Oncology • Austin, TX

Genitourinary Oncology

Director of the Prostate and Urologic Cancer Research Program, Texas Oncology

Join to view full profile

Dr. Lattanzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lattanzi's full profile

Already have an account?

  • Office

    6204 Balcones Dr
    Austin, TX 78731
    Phone+1 512-427-9400
    Fax+1 512-342-2723

Summary

  • Genitourinary Medical Oncology and Clinical Trials

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2016 - 2019
  • New York University School of Medicine
    New York University School of MedicineClass of 2016

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2022 - 2025
  • NC State Medical License
    NC State Medical License 2022 - 2023
  • NY State Medical License
    NY State Medical License 2019 - 2022
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunot... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • ESMO 2019: TROPHY-U-01: Initial Results of a Phase 2 Open-Label Study of Sacituzumab Givotecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or Immunotherapy
    ESMO 2019: TROPHY-U-01: Initial Results of a Phase 2 Open-Label Study of Sacituzumab Givotecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or ImmunotherapySeptember 29th, 2019
  • ESMO 2019: Single Agent Immune Therapy and Immune Combinations
    ESMO 2019: Single Agent Immune Therapy and Immune CombinationsOctober 1st, 2019

Dr. Michael Lattanzi, Dr. Michael Lattanzi, MD, Dr. M Lattanzi, Dr. Michael William Lattanzi